User profiles for K. Paull

Kateri Paul

Verified email at parc.com
Cited by 8986

[PDF][PDF] Unconventional methods for fabricating and patterning nanostructures

Y Xia, JA Rogers, KE Paul… - Chemical …, 1999 - projects.iq.harvard.edu
Fascinating (and sometimes technologically important) phenomena occur in systems that
have a spatial dimension comparable to that of a fundamental physical, chemical, or biological …

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines

…, P Skehan, R Shoemaker, K Paull… - JNCI: Journal of the …, 1991 - academic.oup.com
We describe here the development and implementation of a pilot-scale, in vitro, anticancer
drug screen utilizing a panel of 60 human tumor cell lines organized into subpanels …

[HTML][HTML] Is forced expiratory volume in one second the best measure of severity in childhood asthma?

JD Spahn, R Cherniack, K Paull… - American journal of …, 2004 - atsjournals.org
This essay focuses on whether FEV1 is the best measure of asthma severity in childhood
asthma. For better or worse, FEV1 has become the gold standard lung function measurement …

Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines

DA Scudiero, RH Shoemaker, KD Paull, A Monks… - Cancer research, 1988 - AACR
We have previously described the application of an automated microculture tetrazolium
assay (MTA) involving dimethyl sulfoxide solubilization of cellular-generated 3-(4,5-…

Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen

MR Boyd, KD Paull - Drug development research, 1995 - Wiley Online Library
During 1985–1990 the US National Cancer Institute (NCI) phased out its murine leukemia
P388 anticancer drug screening program and developed as the replacement a new in vitro …

An information-intensive approach to the molecular pharmacology of cancer

…, VN Viswanadhan, GS Johnson, RE Wittes, KD Paull - Science, 1997 - science.org
Since 1990, the National Cancer Institute (NCI) has screened more than 60,000 compounds
against a panel of 60 human cancer cell lines. The 50-percent growth-inhibitory …

Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor

…, NG Ahn, MK Oskarsson, K Fukasawa, KD Paull… - Science, 1998 - science.org
Anthrax lethal toxin, produced by the bacterium Bacillus anthracis, is the major cause of
death in animals infected with anthrax. One component of this toxin, lethal factor (LF), is …

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm

KD Paull, RH Shoemaker, L Hodes… - JNCI: Journal of the …, 1989 - academic.oup.com
The objective of this study was to develop and investigate an approach to optimally detect,
rank, display, and analyze patterns of differential growth inhibition among cultured cell lines. …

Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines

LV Rubinstein, RH Shoemaker, KD Paull… - JNCI: Journal of the …, 1990 - academic.oup.com
The National Cancer Institute (NCI) is implementing a large-scale in vitro drug-screening
program that requires a very efficient automated assay of drug effects on tumor cell viability or …

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug …

…, M Alvarez, R Parker, E Reed, K Paull… - Biochemical …, 1996 - Elsevier
The present study was designed to explore the activity of platinum compounds in cisplatinresistant
cell lines, the unselected cell lines of the National Cancer Institute's Anticancer Drug …